Drug General Information (ID: DDIYXPDIAT)
  Drug Name Isoflurophate (ophthalmic) Drug Info Thalidomide Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Ophthalmic Glaucoma Agents Immunosuppressive Agents
  Structure

 Mechanism of Isoflurophate (ophthalmic)-Thalidomide Interaction (Severity Level: Moderate)
     Increased risk of ventricular arrhythmias Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Isoflurophate (ophthalmic) Thalidomide
      Mechanism Prolong QT interval Bradycardia
      Key Mechanism Factor 1
Factor Name Ventricular arrhythmias
Factor Description Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
      Mechanism Description
  • Increased risk of ventricular arrhythmias by the combination of Isoflurophate (ophthalmic) and Thalidomide 

Recommended Action
      Management Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat. A dose reduction of thalidomide or discontinuation may be required.

References
1 Cerner Multum, Inc. "Australian Product Information.".
2 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.